Key result
LVH in HFmrEF is linked to a ~4-fold higher atherogenic index of plasma.
Why the study?
It was unknown whether an association exists between lipid indices and the development of left ventricular hypertrophy in patients with HFmrEF.
Is the atherogenic index of plasma associated with left ventricular hypertrophy in patients with HFmrEF and normal lipid profiles?
Case-Control (n=78)
No
Is the atherogenic index of plasma associated with left ventricular hypertrophy in patients with HFmrEF and normal lipid profiles?
Answers are grounded in this paper and cite their sources.
In patients with HFmrEF and normal lipid profiles, a higher atherogenic index of plasma is associated with the presence of left ventricular hypertrophy.
Aim: The aim of the present study was to investigate whether an association between lipid indices- atherogenic index of plasma (AIP), Castelli Risk Index I (CRI-I), Castelli Risk Index II (CRI-II) and triglyceride index (TGL-index) and the development of left ventricular hypertrophy exists in patients with heart failure with mid-range ejection fraction (HFmrEF). Material and methods: The study involved 56 patients with HFmrEF and normal lipid profile, median age 64 (47-84) and 22 healthy subjects, median age 58 (51-69). The patients were divided in two subgroups: subjects with left ventricular hypertrophy (n=32); (HFmrEF+LVH) and subjects without left ventricular hypertrophy (n=24); (HFmrEF-LVH). The lipid profile was measured by laboratory, while lipid indices were calculated, using the established formulas. Results: There was not statistically significant difference between the lipid indices in patients with heart failure with mid-range ejection fraction compared to healthy controls (p>0.05). HFmrEF+LVH patients showed statistically significantly higher values of atherogenic index of plasma than HFrEF-LVH patients: 0.16 (0.05/0.37) vs. 0.04 (0.01/0.11); (KW=5.80; p=0.02). TC/HDL, LDL/HDL and TG/HDL values were not significantly higher in HFmrHEF+LVH than HFmrEF-LVH patients: 4.8 (3.98/5.75) vs. 4.49 (3.58/5.63); 2.91 (2.1/4.0) vs. 2.9 (2.5/4.25) and 1.36 (1.11/2.08) vs. 1.13 (0.9/1.53), respectively (p>0.05). No significant gender differences between lipid indices were found. Atherogenic index of plasma showed correlation with LVH (r=0.45; p=0.01) and interventricular septum thickness (r=0.55; p=0.002). Conclusion: Our findings show an association between atherogenic index of plasma and LVH in patients with HFmrEF with normal lipid profile. Further studies are warranted to confirm whether determination of AIP may be used for monitoring development and progression of left ventricular hypertrophy in heart failure with mid-range ejection fraction.
No takes yet. Share an insight, caveat, or question.
Николов et al. (2022) conducted a case-control in Chronic heart failure with mid-range ejection fraction (HFmrEF) (n=78). Atherogenic index of plasma (AIP) vs. Patients without left ventricular hypertrophy (HFmrEF-LVH) was evaluated on Atherogenic index of plasma (AIP) value (p=0.02). Atherogenic index of plasma was significantly higher in heart failure patients with mid-range ejection fraction and left ventricular hypertrophy compared to those without hypertrophy (0.16 vs 0.04, p=0.02).
Synapse has enriched 10 related papers. Consider them for comparative context: